Notícias e Atividades da Avenzo Therapeutics

Fusão, aquisição e financiamento envolvendo Avenzo Therapeutics.

• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Veja o organograma con seus 33 executivos principais

Biografias mais buscadas da Avenzo Therapeutics

• Athena Countouriotis, Co-Founder, Chief Executive Officer and Chai...
• Simeon George, Director
• Garry Nicholson, Independent Director

Recentes movimentos de executivos em Avenzo Therapeutics

• Sherry Wunder antes Director, Clinical Data Management, foi promovido a Senior Director, Clinical Data Management  (Notícia publicada em 31 de março de 2026).
• Heather Sun antes Director, Business Development, foi promovido a Senior Director, Business Development  (Notícia publicada em 31 de março de 2026).
• Robyn Gavin antes Associate Director, Medical Writing, foi promovido a Director, Medical Writing  (Notícia publicada em 31 de março de 2026).

Clique aqui para ver outras movimentos em Avenzo Therapeutics

Criar um alerta
para seguir os movimentos de executivos da Avenzo Therapeutics.

Avenzo Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Avenzo Therapeutics

• Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study | Avenzo Therapeutics
• Avenzo Therapeutics to Present Updated Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting | Avenzo Therapeutics
• Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium | Avenzo Therapeutics
• Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin | Avenzo Therapeut
• Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer | Avenzo Therapeutics
• Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC | Avenzo Therapeutics
• Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium | Avenzo Therapeutics
• Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate | Avenzo Therapeutics
• Avenzo Therapeutics Announces $60 Million Series B Financing | Avenzo Therapeutics
• Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate | Avenzo Therapeutics
• View more press releases Close

Redes sociais sobre Avenzo Therapeutics

• Avenzo Therapeutics na Wikipedia, Google News e Yahoo Finance
• Avenzo Therapeutics na LinkedIn, X (Twitter) e YouTube